Biolargo director granted stock options for fees

Biolargo, Inc. director Linda Park received a stock option grant as board compensation.

Rhea-AI Filing Summary

Biolargo, Inc. director Linda Park received a stock option grant as board compensation. On the reported date, she was granted an option to purchase 115,741 shares of common stock at an exercise price of $0.162 per share, expiring on March 31, 2036.

The footnote explains this option was issued in lieu of $18,750 in cash fees for her most recently completed quarterly board service, under Biolargo’s 2024 Equity Incentive Plan. Following this grant, her directly held derivative position is reported as 1,381,502 option-linked shares.

Insider Trade Summary

Grant/Award: 115,741 shares

Grant/Award 1 txn

Insider Park Linda

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	115,741	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 1,381,502 contracts (Direct)

Footnotes (1)

1. F1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

Key Figures

Option grant size: 115,741 shares Exercise price: $0.162 per share Board fees satisfied: $18,750 +2 more

5 metrics

Option grant size 115,741 shares Underlying common stock in new option grant

Exercise price $0.162 per share Exercise price of granted stock options

Board fees satisfied $18,750 Fees replaced by stock option grant for quarterly service

Total derivative shares after grant 1,381,502 shares Total shares underlying options following transaction

Option expiration date March 31, 2036 Expiration of granted stock options

Key Terms

Option to Purchase Common Stock, 2024 Equity Incentive Plan, Grant, award, or other acquisition, derivative

4 terms

Option to Purchase Common Stock financial

"security_title: "Option to Purchase Common Stock""

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan."

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

derivative financial

"transaction_type: "derivative""

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Biolargo (BLGO) director Linda Park report?

Linda Park reported receiving a stock option grant as compensation. She was granted options for 115,741 shares of Biolargo common stock, documented as a derivative acquisition on Form 4, rather than an open-market purchase or sale of existing shares.

How many Biolargo (BLGO) shares are covered by Linda Park’s new option grant?

The new option grant covers 115,741 shares of Biolargo common stock. This derivative award increases her reported derivative holdings, with total shares underlying options reported at 1,381,502 following the transaction in the Form 4 filing.

What is the exercise price and expiration date of Linda Park’s Biolargo options?

The stock options granted to Linda Park have an exercise price of $0.162 per share and expire on March 31, 2036. These terms define the cost to acquire shares and the final date by which the options can be exercised.

How was Linda Park’s Biolargo (BLGO) option grant linked to her board fees?

The option was issued instead of $18,750 in cash fees owed for her most recent quarterly board service. The number of option shares equals the fee amount divided by the $0.162 exercise price, under Biolargo’s 2024 Equity Incentive Plan.

Is Linda Park’s Form 4 transaction in Biolargo stock a market buy or sell?

The filing shows a grant of derivative securities, not an open-market trade. Code “A” reflects a grant or award acquisition of options, issued as board compensation, rather than a discretionary purchase or sale of Biolargo common stock in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 07:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Park Linda

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CALIFORNIA 92683

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.162	03/31/2026		A		115,741		03/31/2026	03/31/2036	Common Stock	115,741	(1)	1,381,502	D

Explanation of Responses:

1. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

	/s/ John R. Browning, attorney-in-fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)